• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Personalized Medicine >Rapid Collection of Biospecimens by Automated Identification of Patients Eligible for Pharmacoepigenetic Studies
【24h】

Rapid Collection of Biospecimens by Automated Identification of Patients Eligible for Pharmacoepigenetic Studies

机译：通过自动识别有资格进行药代遗传学研究的患者，快速收集生物标本

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Epigenetics plays an important role in regulating gene expression, and can be modified by environmental factors and physiological conditions. Studying epigenetics is a promising approach to potentially improving the diagnosis, prevention and treatment of human diseases, and to providing personalized medical care. However, the role of epigenetics in the development of diseases is not clear because epigenetic markers may be both mediators and outcomes of human diseases. It is particularly complicated to study pharmacoepigenetics, as medication use may modify the epigenetic profile. To address the challenges facing pharmacoepigenetic research of human diseases, we developed a novel design to rapidly identify, contact, and recruit participants and collect specimens for longitudinal studies of pharmacoepigenetics. Using data in real-time from electronic medical record systems, we can identify patients recently start on new medications and who also have a blood test. Prior to disposal of the leftover blood by the clinical laboratory, we are able to contact and recruit these patients, enabling us to use both their leftover baseline blood sample as well as leftover specimens at future tests. With treatment-naïve and follow-up specimens, this system is able to study both epigenetic markers associated with disease without treatment effect as well as treatment-related epigenetic changes.
机译：表观遗传学在调节基因表达中起着重要作用，并且可以被环境因素和生理条件所修饰。研究表观遗传学是一种有前途的方法，可以潜在地改善人类疾病的诊断，预防和治疗，并提供个性化的医疗服务。然而，表观遗传学在疾病发展中的作用尚不清楚，因为表观遗传学标记可能既是人类疾病的媒介，又是人类疾病的结果。研究药物表观遗传学特别复杂，因为药物的使用可能会改变表观遗传学特征。为了应对人类疾病的药物表观遗传学研究面临的挑战，我们开发了一种新颖的设计来快速识别，联系和招募参与者，并收集用于药物表观遗传学纵向研究的标本。使用电子病历系统中的实时数据，我们可以识别出最近开始使用新药物并且也进行血液检查的患者。在临床实验室处置剩余血液之前，我们能够联系并招募这些患者，使我们能够在未来的测试中使用他们的剩余基线血液样本和剩余标本。利用未进行治疗的样本和后续样本，该系统能够研究与疾病相关的表观遗传标记而无治疗效果，以及与治疗相关的表观遗传变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号